Investor Relations
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>
Sep 11, 2018
OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock MORE >>
Sep 07, 2018
OPKO Comments on SEC Complaint MORE >>
Sep 04, 2018
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients MORE >>

Press Releases

All Releases
OPKO Health Expands Portfolio of Tests for Inherited Forms of Cancer
Oct 22, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that its GeneDx business unit has expanded its inherited cancer panel offerings and genetic tests to include four additional genes. The four genes are POLD1, POLE, SCG5/GREM1, and SMARCA4.
OPKO Health's GeneDx business Presenting at National Society of Genetic Counselors Annual Meeting
Oct 21, 2015
Focus is on Genetic Diagnosis of Rare Disease PITTSBURGH --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that GeneDx, a business unit of OPKO will be presenting at the National Society of Genetic Counselors (NSGC) 34 th Annual Education Conference in Pittsburgh, PA.
Vanderbilt University School of Medicine and OPKO Health Collaborate on Genomics
Oct 13, 2015
New Tumor Sequencing Panel Aims to Improve Patient Care and Accelerate Discovery MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today a collaboration among its subsidiary, BioReference Laboratories, Inc. , the Department of Pathology , Microbiology, and Immunology and the
OPKO to Host Symposium to Present Clinical Data on its Long-acting Human Growth Hormone at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology
Oct 08, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the company will host a symposium at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology and will present the complete 12-month pharmacokinetic, pharmacodynamic, safety and efficacy data of OPKO's
OPKO Presents Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) in Two Oral Presentations at the 54th Annual Meeting of the European Society for Pediatric Endocrinology (ESPE)
Oct 07, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) presented clinical data from its completed 12-month hGH-CTP Phase 2 pediatric growth hormone deficiency clinical study in two oral presentations at the 54th Annual Meeting of the European Society for Paediatric Endocrinology on October 3, 2015
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes
Oct 01, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the Company's 3.0% Convertible Senior Notes due 2033 (the "Notes") continue to be convertible by holders of such Notes through December 31, 2015 . The Company has elected to satisfy its conversion obligation under the
OPKO Health to Present at the Ladenburg Thalmann 2015 Healthcare Conference
Sep 22, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29 th , 2015 at 11:00 AM (ET) . Management will be available for one on one meetings. About OPKO Health, Inc.
OPKO Health Announces Global License Agreement for the Discovery of Novel Antimicrobials
Sep 09, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced a global license agreement with The Scripps Research Institute (TSRI) for the development and commercialization of novel lipoprotein signal peptidase ("Lsp") inhibitors developed and discovered using a proprietary high
OPKO Licensee TESARO Receives FDA Approval for VARUBI™ (rolapitant)
Sep 02, 2015
VARUBI™ to Address a Potential U.S. Market Opportunity That Exceeds $1 Billion U.S. Commercial Launch Planned for Q4 2015; OPKO to Receive up to $110 million of Milestone Payments and Double Digit tiered Royalties MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), today announced that the U.S.
OPKO Letter to Shareholders
Aug 26, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today released the following open letter from Phillip Frost , M.D., its Chairman and Chief Executive Officer, to its shareholders: Dear Shareholder, I want to take the occasion of OPKO's recently announced acquisition of Bio-Reference
OPKO Health to Be Present at the Barrington Research Fall Investment Conference
Aug 25, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will attend the Barrington Research Fall Investment Conference on Tuesday, September 1, 2015 in Chicago and will be available for one on one meetings. About OPKO Health, Inc.
OPKO Completes Acquisition of Bio-Reference Laboratories
Aug 20, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) today announced the completion of the acquisition of Bio-Reference by OPKO. Shareholders of Bio-Reference will receive 2.75 shares of OPKO common stock for each share of Bio-Reference common
OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services Including the 4Kscore® Test
Aug 19, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that it has entered into agreements with Stratose , Three Rivers Provider Network and Fortified Provider Network for testing services from OPKO Lab , including the 4Kscore®Test, the only blood test that accurately identifies an
OPKO Announces Second Quarter Operating and Financial Results
Aug 05, 2015
Announced the Acquisition of Bio-Reference Laboratories; Closing Anticipated by the End of August Acquired EirGen Pharma , A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer Rayaldee TM New Drug Application (NDA) Submission Accepted by FDA ; Expected PDUFA date of March 29,
Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE conference)
Aug 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), announced that additional data from OPKO's hGH-CTP pediatric Phase 2 clinical trials summarized in two abstracts entitled, " 12 month Safety and efficacy of a weekly long-acting growth hormone (GH, MOD-4023) compared to daily recombinant human
OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015
Jul 30, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will announce second quarter 2015 operating and financial results on Wednesday August 5th , after the close of the U.S. financial markets. OPKO's senior management will host a conference call and live audio webcast to provide a business
FDA Accepts OPKO's New Drug Application for Rayaldee™
Jul 28, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review OPKO's New Drug Application (NDA) for calcifediol modified-release capsules (proposed trade name, Rayaldee™).
OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults
Jul 10, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE:OPK) has completed enrollment in the single pivotal Phase 3 trial of its long acting human growth hormone (hGH-CTP) in growth hormone deficient (GHD) adults. The trial is designed to evaluate the safety and efficacy of hGH-CTP with a primary
OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources
Jul 10, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) is pleased to announce that SciVac Ltd. (" SciVac "), an Israeli entity in which OPKO has a forty-five percent ownership interest, completed its previously announced plan of arrangement under Section 288 of the Business Corporations Act (
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition
Jul 02, 2015
  MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (OPK) and Bio-Reference Laboratories, Inc. (BRLI), today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has been granted, effective July 1, 2015 , for OPKO's
Displaying 121 - 140 of 363